Mode
Text Size
Log in / Sign up

Polypharmacy and age predict MACE in rural Montana type 2 diabetes cohortIn rural diabetes care, does taking more medications signal higher heart risk?

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider medication count and age as predictors of MACE in rural diabetes patients, but recognize these are observational associations.

This observational cohort study analyzed 591 patients with type 2 diabetes from the Big Sky Care Connect Database in rural Montana. Patients were stratified by prescribed medication count: 1-4 medications (non-polypharmic), 5-9 medications (polypharmic), and ≥10 medications (hyperpolypharmic). The primary outcome was not explicitly stated, but secondary outcomes included Major Adverse Cardiovascular Events (MACE) and Diabetes Complication Severity Index (DCSI).

Multivariate analysis showed medication count and age were significant predictors of MACE, with an incidence rate ratio (IRR) of 1.06 per additional medication and 1.03 per year of age (p < 0.001 for both). Neuropathy and nephropathy prevalence also increased significantly across patient cohorts with higher medication counts (p < 0.001). Medication count was negatively associated with male gender (β = -2.1341, p < 0.001).

Safety and tolerability data were not reported. Key limitations include the observational design, which cannot establish causality, and the lack of reported follow-up duration. The study population was specific to rural Montana, which may limit generalizability. Funding sources and conflicts of interest were not reported.

For practice, these findings highlight associations between polypharmacy and adverse outcomes in a rural diabetes population. The results may inform strategies to improve medication adherence and reduce preventable complications in underserved regions, but clinical decisions should not be based solely on these observational associations.

Managing type 2 diabetes often means juggling multiple medications. A new look at health records from 591 patients in rural Montana suggests that the sheer number of prescriptions a person takes might be a warning sign. The research found that a higher medication count, along with older age, was significantly linked to a greater likelihood of experiencing major adverse cardiovascular events (MACE), which include heart attacks and strokes. The study also showed that common diabetes complications like nerve damage (neuropathy) and kidney problems (nephropathy) were more prevalent in patients taking more medications.

It's crucial to understand what this data does and doesn't tell us. This was an observational study, meaning researchers looked back at existing records. They found an association, but they cannot prove that taking more medications causes heart problems. It's very possible that people who need more medications are already sicker with more severe diabetes, which itself raises heart risk.

The patients were all from one rural database in Montana, which helps us understand challenges in underserved areas but means the findings might not apply to everyone with diabetes. The study didn't report on side effects or why people were on so many drugs. The key takeaway isn't that medications are bad—they are essential for control—but that a high medication count could be a red flag. It might point to a person whose diabetes is complex and who could benefit from a careful review of their overall care plan to ensure every pill is truly necessary and working as intended.

What this means for you:
In rural diabetes patients, more medications linked to higher heart risk, but this shows association, not cause.

Study Details

Study typeCohort
Sample sizen = 591
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Objective: In this study, we utilized a large-scale clinical database to evaluate the relationship between polypharmacy and adverse outcomes among type 2 diabetes patients in rural Montana to inform strategies that improve adherence, reduce preventable complications, and promote equitable diabetes care in underserved regions. Research Design and Methods: 591 patients from the Big Sky Care Connect Database (BSCC) with type 2 diabetes and medication history were stratified into 3 cohorts based on prescribed number of medications: (1-4 medications, non-polypharmic), (5-9 medications, polypharmic), and ([&ge;]10 medications, hyperpolypharmic). Each cohort was examined for Major Adverse Cardiovascular Events (MACE) and Diabetes Complication Severity Index (DCSI). Descriptive statistics, multivariate logistic regressions, linear regression, and Poisson regression analyses were performed. Results: Medication count was associated with male gender ({beta} = -2.1341, p < 0.001). Both medication count (IRR 1.06 per additional medication, p < 0.001) and age (IRR 1.03 per year, p < 0.001) were significant predictors of MACE. Neuropathy and nephropathy prevalence was statistically significant (p < 0.001) across patient cohorts and increased with medication count.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.